{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:38:06Z","timestamp":1789079886358,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.kint.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T09:31:09Z","timestamp":1781775069000},"page":"29-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A potential role for effector T cells with Fc receptors in kidney transplant antibody-mediated rejection"],"prefix":"10.1016","volume":"110","author":[{"given":"Patrick T.","family":"Gauthier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip F.","family":"Halloran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.04.011_bib1","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1172\/JCI66722","article-title":"Cognate antigen directs CD8+ T cell migration to vascularized transplants","volume":"123","author":"Walch","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.04.011_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.011_bib3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","article-title":"Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies","volume":"31","author":"Diebold","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.04.011_bib4","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ajt.17092","article-title":"Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes","volume":"22","author":"Halloran","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.04.011_bib5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1681\/ASN.2020030306","article-title":"Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies","volume":"31","author":"Callemeyn","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.011_bib6","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1681\/ASN.2020111558","article-title":"Missing self-induced microvascular rejection of kidney allografts: a population-based study","volume":"32","author":"Callemeyn","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.011_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajt.2024.07.034","article-title":"Subthreshold rejection activity in many kidney transplants currently classified as having no rejection","volume":"25","author":"Halloran","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.04.011_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65153-9","article-title":"Continuous indices to assess the phenotypic spectrum of kidney transplant rejection","volume":"16","author":"Vaulet","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.04.011_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.kint.2026.03.012","article-title":"Intragraft clonal expansion of cytotoxic CD8+ and CD4+ T cells in antibody-mediated kidney transplant rejection","volume":"110","author":"Vaulet","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.011_bib10","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1074\/jbc.M114.599266","article-title":"Induced expression of FcgammaRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-gammahigh subset","volume":"290","author":"Chauhan","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.04.011_bib11","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.4049\/jimmunol.1900422","article-title":"Terminal effector CD8 T cells defined by an IKZF2(+)IL-7R(-) transcriptional signature express FcgammaRIIIA, expand in HIV infection, and mediate potent HIV-specific antibody-dependent cellular cytotoxicity","volume":"203","author":"Naluyima","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.04.011_bib12","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.4049\/jimmunol.181.6.4219","article-title":"Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection","volume":"181","author":"Bjorkstrom","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.04.011_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1600-6143.2007.02128.x","article-title":"The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells","volume":"8","author":"Hidalgo","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.04.011_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s13063-022-06897-3","article-title":"Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: phase 3 IMAGINE study rationale and design","volume":"23","author":"Nickerson","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.kint.2026.04.011_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.13436","article-title":"The therapeutic challenge of late antibody-mediated kidney allograft rejection","volume":"32","author":"Bohmig","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2026.04.011_bib17","unstructured":"A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) (TRANSCEND). ClinicalTrials.gov Identifier: NCT06685757. Updated March 12, 2026. Accessed March 25, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06685757"},{"key":"10.1016\/j.kint.2026.04.011_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajt.2025.07.1641","article-title":"Trial design of the phase 2 study SHAMROCK evaluating the safety, tolerability, and efficacy of Efgartigimod PH20 SC in adult kidney transplant recipients with antibody-mediated rejection","volume":"25","author":"Bohmig","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2026.04.011_bib18","unstructured":"A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (TRANSPIRE). ClinicalTrials.gov Identifier: NCT07219043. Updated April 27, 2026. Accessed March 25, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07219043"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826003248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:55:52Z","timestamp":1787172952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826003248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0085253826003248"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.011","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potential role for effector T cells with Fc receptors in kidney transplant antibody-mediated rejection","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.03.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}